Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...

Discover how UCSF is leading the charge in Long COVID research, uncovering key findings that advance our understanding of the condition. UCSF researchers have adapted innovative tools and ...

Lithium, a widely used treatment for bipolar disorder and other mood disorders, has shown early promise in suppressing HIV, ...

Rwanda reported a drop in new HIV infections in 2024, with 2,555 people diagnosed, down from about 2,922 in 2023. The decline ...

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.

We’re all mostly human. 8% of your genome comes from viruses. In A Nutshell Scientists captured the first detailed images of HERV-K, a viral protein found in cancer cells, lupus, and ALS patients HERV ...

Human immunodeficiency virus (HIV) infections are still fairly common and an estimated 40 million people worldwide are currently living with this condition. The HIV virus attacks the body's immune ...

After receiving a series of immunotherapies, most people with HIV in a small study kept their virus levels low for several months—and one person for more than a year and a half—without their usual ...

Heat shock proteins (HSPs) are essential molecular chaperones involved in protein folding, cellular stress responses, and homeostasis. Recent studies reveal their critical and dual roles in the human ...

A man has become the seventh person to be left HIV-free after receiving a stem cell transplant to treat blood cancer. Significantly, he is also the second of the seven who received stem cells that ...

SINCE the 1980s, researchers have worked tirelessly to develop effective treatments that can suppress the HIV virus to undetectable levels. As a result, by taking a single daily dose of an ...